Gastric Cancer
📧 Sign up to get email alerts when something new happens for Gastric Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-15FDA Approved: ONTRUZANT — Supplemental Application (Organon LLC)
FDA approved a supplemental application for ONTRUZANT (trastuzumab) submitted by Organon LLC. The approval encompasses labeling updates rela…
-
EMA approval · 2026-03-03EMA Authorised: Vyloy (zolbetuximab) — Astellas Pharma Europe B.V.
EMA authorised Vyloy (zolbetuximab) for gastric and esophageal cancers; the medicine has orphan designation and is developed by Astellas Pha…
-
EMA approval · 2026-02-23EMA Authorised: Ogivri (trastuzumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Ogivri, a trastuzumab biosimilar from Biosimilar Collaborations Ireland Limited, for gastric cancer and breast cancer.
-
EMA approval · 2026-01-26EMA Authorised: Tevimbra (tislelizumab) — Beone Medicines Ireland Limited
EMA authorised Tevimbra (tislelizumab) from Beone Medicines Ireland Limited for multiple cancer indications, including esophageal squamous c…
-
EMA approval · 2026-01-23EMA Authorised: Ontruzant (trastuzumab) — Samsung Bioepis NL B.V.
EMA authorised Ontruzant (trastuzumab) from Samsung Bioepis NL B.V., a biosimilar to trastuzumab for breast and gastric cancers.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-16EMA Authorised: Cyramza (ramucirumab) — Eli Lilly Nederland B.V.
The EMA has authorised Cyramza (ramucirumab) for gastric cancer (stomach neoplasms) in the European Union, with Eli Lilly Nederland B.V. as …
-
FDA approval · 2026-01-15FDA Approved: OXALIPLATIN — Original Application (Shandong New Time Pharmaceutical Co., Ltd.)
The FDA approved Shandong New Time Pharmaceutical Co., Ltd.'s original application for a generic oxaliplatin injection, enabling its manufac…
-
FDA approval · 2025-11-12FDA Tentative Approval: FLUOROURACIL — Supplemental Application (Gland Pharma Limited)
FDA Tentative Approval for Fluorouracil from Gland Pharma Limited under an ANDA, indicating a pathway to U.S. market subject to regulatory t…
-
EMA approval · 2025-10-20EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH
EMA authorised Herwenda, a trastuzumab biosimilar by Sandoz GmbH, for certain HER2-positive cancers. Approved indications include breast can…
-
FDA approval · 2025-08-21FDA Approved: TRAZIMERA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TRAZIMERA (trastuzumab-qyyp) from Pfizer Laboratories Div Pfizer Inc, authorizing changes under …
-
FDA approval · 2025-06-06FDA Approved: VYLOY — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for VYLOY (zolbetuximab) from Astellas Pharma US, expanding/updating its labeling.
-
FDA approval · 2025-05-22FDA Approved: HERZUMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for Herzuma (trastuzumab) from Cephalon, Inc.
-
EMA approval · 2025-05-13EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.
The European Medicines Agency authorised Kanjinti (trastuzumab) by Amgen Europe B.V. for gastric and breast cancers.
-
FDA approval · 2025-05-13FDA Approved: DOCETAXEL — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approves a generic docetaxel product under an original ANDA for Meitheal Pharmaceuticals Inc.
-
EMA approval · 2025-05-05EMA Authorised: Ecansya (previously Capecitabine Krka) (capecitabine) — Krka, d.d., Novo mesto
The EMA authorised Ecansya, a capecitabine product by Krka, as a new generic cancer treatment option for breast, colon, colorectal, and gast…
-
EMA approval · 2025-05-02EMA Authorised: Xeloda (capecitabine) — CHEPLAPHARM Arzneimittel GmbH
The EMA authorised CHEPLAPHARM Arzneimittel GmbH to market Xeloda (capecitabine) in the EU for several cancers, including breast, colon/colo…
-
FDA approval · 2025-02-28FDA Approved: ONTRUZANT — Supplemental Application (Organon LLC)
FDA approved a supplemental application for ONTRUZANT (trastuzumab) by Organon LLC. This document confirms the supplemental approval for the…
-
FDA approval · 2025-01-27FDA Approved: CYRAMZA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for CYRAMZA (ramucirumab) from Eli Lilly and Company.
-
CLINICAL_TRIALS approval · 2025-01-09Clinical Trial Update: International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
An international expanded-access program for ramucirumab has been established to treat metastatic gastric cancer and metastatic adenocarcino…
-
CLINICAL_TRIALS approval · 2025-01-09Clinical Trial Update: Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
France granted a temporary authorization for use (ATU) of ramucirumab in combination with paclitaxel for gastric or gastroesophageal junctio…
-
FDA approval · 2024-11-22FDA Approved: PHESGO — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for PHESGO, the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf, submitted…
-
FDA approval · 2024-11-13FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for OGIVRI (trastuzumab-dkst) from Biocon Biologics Inc.
-
FDA approval · 2024-10-18FDA Approved: VYLOY — Original Application (Astellas Pharma US, Inc.)
FDA approved the original Biologics License Application for VYLOY (zolbetuximab) from Astellas Pharma US, enabling its use for a gastric/gas…
-
EMA approval · 2024-07-31EMA Authorised: Taxotere (docetaxel) — Sanofi Winthrop Industrie
The EMA authorised Taxotere (docetaxel) for multiple cancer indications including head and neck cancer, non-small cell lung cancer, gastric …
-
FDA approval · 2024-04-15FDA Approved: CAPECITABINE — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for Capecitabine, updating regulatory status for this cancer drug. The action lik…